Should I buy or sell Terumo stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TRUMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRUMY, but not buy additional shares or sell existing shares. View TRUMY analyst ratings or view top-rated stocks .

How have TRUMY shares performed in 2024?

Terumo's stock was trading at $16.31 at the start of the year. Since then, TRUMY stock has increased by 2.3% and is now trading at $16.69. View the best growth stocks for 2024 here .

Are investors shorting Terumo?

Terumo saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,600 shares, an increase of 271.4% from the March 15th total of 700 shares. Based on an average daily trading volume, of 30,200 shares, the days-to-cover ratio is presently 0.1 days. View Terumo's Short Interest .

How were Terumo's earnings last quarter?

Terumo Co. (OTCMKTS:TRUMY) released its earnings results on Wednesday, February, 7th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. The company earned $1.62 billion during the quarter. Terumo had a trailing twelve-month return on equity of 8.26% and a net margin of 11.14%.

Is Terumo a good dividend stock?

Terumo (OTCMKTS:TRUMY) pays an annual dividend of $0.11 per share and currently has a dividend yield of 0.64%. The dividend payout ratio is 23.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TRUMY will have a dividend payout ratio of 16.42% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Terumo's stock split?

Terumo's stock split before market open on Thursday, March 28th 2024. The 2-1 split was announced on Thursday, March 28th 2024. The newly created shares were issued to shareholders after the market closes on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How do I buy shares of Terumo?

Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:TRUMY

Terumo (TRUMY) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free TRUMY Stock Alerts

$16.69

-0.30 (-1.77%)

(As of 04/17/2024 05:34 PM ET)

Compare

Today's Range: $16.35
▼
$17.36
50-Day Range: $16.53
▼
$36.78
52-Week Range: $12.56
▼
$20.60

Volume: 45,626 shs
Average Volume: 50,997 shs
Market Capitalization: $24.88 billion

P/E Ratio: 35.14
Dividend Yield: 0.66%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades SEC Filings Short Interest

Get Terumo alerts:

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Terumo Stock (OTCMKTS:TRUMY)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

TRUMY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRUMY Stock News Headlines

March 18, 2024 | finance.yahoo.com

Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength

February 14, 2024 | finanznachrichten.de

Terumo Blood and Cell Technologies: Hundreds of sickle cell patients to benefit from £1.5M technology investment

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

January 26, 2024 | finance.yahoo.com

Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable

January 17, 2024 | seekingalpha.com

Improved Revenue Growth Is Terumo's Next Major Target

January 10, 2024 | finance.yahoo.com

Recent Price Trend in Terumo Corp. (TRUMY) is Your Friend, Here's Why

December 17, 2023 | msn.com

Terumo Corporation - ADR (TRUMY) Price Target Increased by 7.08% to 37.31

December 13, 2023 | finance.yahoo.com

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

December 11, 2023 | finance.yahoo.com

Terumo Medical Corporation's New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy

September 26, 2023 | finance.yahoo.com

Terumo's (TRUMY) MicroVention Enters Transradial Access Space

September 22, 2023 | finance.yahoo.com

MicroVention Enters Transradial Access Therapy; Receives FDA Clearance of SOFIA™ EX 5F 115cm Intracranial Support Catheter

June 22, 2023 | marketwatch.com

Ventricular Assist Device Market Growth, Size, Share, Trends, Analysis, Forecast 2023-2031

June 21, 2023 | finance.yahoo.com

Global MedTech CRO, NAMSA, Announces Strategic Outsourcing Partnership With Terumo Aortic

June 19, 2023 | msn.com

Japan stocks lower at close of trade; Nikkei 225 down 1.00%

June 16, 2023 | benzinga.com

Neurovascular Catheters Market to reach USD 7.5 billion in 2032, expanding at a CAGR of 7.9%: TMR Report

June 15, 2023 | benzinga.com

Global Blood Collection Tubes Market Report 2023: Increasing Prevalence of Chronic Diseases Bolsters Growth

June 13, 2023 | finance.yahoo.com

Area hospitals using AI to improve processes, patient outcomes

April 9, 2023 | cbsnews.com

Lakewood Company Putting People at Risk?

March 1, 2023 | benzinga.com

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

February 18, 2023 | washingtonpost.com

The Georgia criminal investigation into Trump and his allies, explained

February 17, 2023 | newsweek.com

Ivanka Trump

February 15, 2023 | finance.yahoo.com

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO

January 31, 2023 | nbcnews.com

Trump kicks off his 2024 campaign: 'We are at the brink of World War III'

January 30, 2023 | time.com

Trump Delivers Bitter Speech Filled With Falsehoods in New Hampshire

January 27, 2023 | forbes.com

Trump Reinstated To Facebook And Instagram

January 27, 2023 | nytimes.com

OMG. Trump Has Started Texting.

See More Headlines

Receive TRUMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terumo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/18/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Medical & hospital equipment
Sub-Industry: N/A
Current Symbol: OTCMKTS:TRUMY
Previous Symbol: NASDAQ:TRUMY
CUSIP: N/A
CIK: 1446672
Web: www.terumo.co.jp
Phone: (133) 374-8111
Fax: 813-3374-8399
Employees: 30,207
Year Founded: 1964

Profitability

EPS (Most Recent Fiscal Year): $0.4750
Trailing P/E Ratio: 35.14
Forward P/E Ratio: 29.28
P/E Growth: N/A
Net Income: $661.01 million
Net Margins: 11.14%
Pretax Margin: N/A
Return on Equity: 8.26%
Return on Assets: 5.89%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 1.90
Quick Ratio: 1.13

Sales & Book Value

Annual Sales: $6.07 billion
Price / Sales: 4.10
Cash Flow: $0.78 per share
Price / Cash Flow: 21.51
Book Value: $5.50 per share
Price / Book: 3.03

Miscellaneous

Outstanding Shares: 1,490,700,000
Free Float: N/A
Market Cap: $24.88 billion
Optionable: Not Optionable
Beta: 0.65

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Shinjiro Sato (Age 64)
Corporate Advisor & Director
Comp: $810.32k
Mr. Hikaru Samejima (Age 60)
President, CEO & Director
Jin Hagimoto
CFO, CIO, GM of CFO Office, Controller & Treasury Tax Dept., J-SOX Office, IT Planning Dept. & GBS
Shinji Omori
CTO, GM of DX Promotion Dept. R&D Division and Executive Officer
Ms. Miho Mizuguchi
Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
Tomoko Adachi
Chief Human Resources Officer & Group Executive Officer
Mr. Shoji Hatano (Age 65)
Director & Corporate Advisor
James Rushworth
Group Executive Officer & Chief Commercial Officer
Mr. Kazunori Hirose (Age 60)
Director & Group Managing Executive Officer
Itaru Sakaguchi
Group Managing Executive Officer

Key Competitors

View All Competitors

Should I Buy Terumo Stock? TRUMY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Terumo Co.:

Terumo's recent stock price performance has shown positive growth, reaching a 52-week high of $41.19, indicating potential for capital appreciation.
Terumo's diversified business segments, including Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies, provide stability and growth opportunities across different healthcare sectors.
Terumo's strong financials, with a market capitalization of $29.04 billion and a healthy debt-to-equity ratio of 0.06, demonstrate financial stability and potential for long-term growth.
Terumo's consistent quarterly earnings performance, meeting analysts' consensus estimates, indicates operational efficiency and management effectiveness.
Terumo's global presence in key markets like Japan, Europe, China, and the United States positions the company for continued international expansion and revenue growth.

Cons

Investors should be bearish about investing in Terumo Co. for these reasons:

Terumo's stock recently experienced a significant increase in short interest, which may indicate potential market volatility or negative sentiment among investors.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Terumo pros and cons to contact@marketbeat.com.

TRUMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Terumo stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TRUMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRUMY, but not buy additional shares or sell existing shares.
View TRUMY analyst ratings or view top-rated stocks.
How have TRUMY shares performed in 2024?: Terumo's stock was trading at $16.31 at the start of the year. Since then, TRUMY stock has increased by 2.3% and is now trading at $16.69.
View the best growth stocks for 2024 here.
Are investors shorting Terumo?: Terumo saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,600 shares, an increase of 271.4% from the March 15th total of 700 shares. Based on an average daily trading volume, of 30,200 shares, the days-to-cover ratio is presently 0.1 days.
View Terumo's Short Interest.
How were Terumo's earnings last quarter?: Terumo Co. (OTCMKTS:TRUMY) released its earnings results on Wednesday, February, 7th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. The company earned $1.62 billion during the quarter. Terumo had a trailing twelve-month return on equity of 8.26% and a net margin of 11.14%.

Is Terumo a good dividend stock?: Terumo (OTCMKTS:TRUMY) pays an annual dividend of $0.11 per share and currently has a dividend yield of 0.64%. The dividend payout ratio is 23.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TRUMY will have a dividend payout ratio of 16.42% next year. This indicates that the company will be able to sustain or increase its dividend.
When did Terumo's stock split?: Terumo's stock split before market open on Thursday, March 28th 2024. The 2-1 split was announced on Thursday, March 28th 2024. The newly created shares were issued to shareholders after the market closes on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
How do I buy shares of Terumo?: Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TRUMY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial